EXELIXIS, INC. - 8-K Filing

Federal Circuit affirms validity of Exelixis' three U.S. patents; generic competitor's FDA approval delayed until January 2030. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $EXEL

Read the full article at SEC EDGAR

More Regulatory news